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Abstract 
This dissertation was written as part of the MSc in Bioeconomy: Biotechnology and 
Law, at the International Hellenic University.  
The work is divided into two large chapters, one concerning the protection of health, 
genetic and biometric data under the scope of the General Data Protection Regulation 
and the relevant national legal frameworks, from Europe and the United States, and 
the second relating to emerging new technologies applicable to the healthcare sector. 
The first part provides a definition of this set of data and the way it was handled and 
regulated from the prior legislation. In addition, a specific emphasis is given in the 
Greek legislation in comparison with other national legal documents from European 
countries, as well as the existing provisions for the protection of sensitive data in the 
United States.  
Secondly, the dissertation aims to provide a comprehensive presentation of new 
technologies that are both amongst the most pioneering of the field but also amongst 
the most popular and incorporate in the life of a large number of the population, being 
either afflicted by a disease or not. Such cases constitute the direct-to-consumer 
genetic testing, mobile health applications, robotics, and AI. They are presented in a 
way that illustrates the legal provisions that regulate them, deriving from different 
parts of the world, like Europe and the US. There is also an examination of the ethical 
questions arising from the use of such technological innovations, and both the 
international and European point of view on the matter.  
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Introduction 
Nowadays after the coming into force of the new General Data Protection Regulation1, 
regulating a need which is the outcome of the advance of technology and the 
capability to store and process an immeasurable amount of data, a new domain of 
research has also immerged, in combination to the evolution in health, genetic and 
biometric data information and innovation technology . 
 Research on the essence and definition of the aforementioned category of 
data, known and described within the Regulation (henceforth GDPR), as sensitive 
personal information, sensitive data, is one of the main objectives of the present 
paper, amongst others. In addition, comparison and alignment of legislative means are 
to be further analyzed considering legal texts and rules produced prior to the GDPR 
and after within the EU borders, such as in Greece2, UK, and Germany, but also outside 
EU regulation and jurisdiction, in the United States related provisions of the matter. 
 Furthermore, as it has been previously mentioned the emergence of new 
technologies capable of combining large amounts of data relating to health, genetic 
and biometric information about individuals, has brought forth the necessity of a high 
level of protection and safeguarding of the process. As a result, principles3 and 
regulations, such as the GDPR, have been issued in an effort to update the law with 
technological innovations such as the Electronic Health Record (henceforth HER), Bio-
banks and Direct to Consumer Genetic Testing, along with Mobile Health Applications, 
Artificial Intelligence technologies and Research & Development projects that involve 
themselves in the field of Robotics, especially in the health care sector and innovations 
in medicine.  
 Technology has allowed the modern society to advance its medical practices 
and treatment of its patients, through the use of the EHR system, the main method, 
and domain where health data are stored, thus the principal technological novelty to 
be examined in this paper, in relation to that form of data. Moreover, as far as it 
comes to genetic data storage, the principal institution(s) in the business of storing 
them on a large scale are bio-banks and most recently direct to consumer genetic 
testing technological companies, which will be the focal point of this analysis. Last but 
not least, biometric data storage and manipulation are frequently found amongst 
mobile health applications, posing a category of their own due to their accessibility by 
the public, alongside though artificial intelligence, algorithms and robotics alike, entail 
a whole new level of controversy on its own.  
                                               
1 Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the 
protection of natural persons with regard to the processing of personal data on the free movement of 
such data, and repealing Directive 95/46/EC (General Data Protection Regulation- GDPR). 
 
2Νόμος 4624/2019, Αρχή Προστασίας Δεδομένων Προσωπικού Χαρακτήρα, μέτρα εφαρμογής του 
Κανονισμού (ΕΕ) 2016/679 του Ευρωπαϊκού Κοινοβουλίου και του Συμβουλίου της 27ης Απριλίου 2016 
για την προστασία των φυσικών προσώπων έναντι της επεξεργασίας δεδομένων προσωπικού 
χαρακτήρα και ενσωμάτωση στην εθνική νομοθεσία της Οδηγίας (ΕΕ) 2016/680 του Ευρωπαϊκού 
Κοινοβουλίου και του Συμβουλίου της 27ης Απριλίου 2016 και άλλες διατάξεις.  
  
3 Centre for Data Ethics and Innovation, ( 12/09/2019), Snapshot Paper - AI and Personal Insurance, 
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/83
1181/Snapshot_Paper_-_AI_and_Personal_Insurance.pdf 
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 The following examination shall be highlighting both the legal and ethical 
questions raised by the newly formed situation in data gathering starting with the 
legislation, providing a comparative work followed by major ethical4 issues, regarding 
the aforementioned technological breakthroughs. Legal texts and their analysis will be 
provided commencing with the most influential one, leading to a European change in 
handling sensitive personal information, the General Data Protection Regulation, 
followed by related national provisions and in contradiction to international ones. 
(Federal5 and non-federal6 acts and statutes legislating relative parts concerning health 
data protection and cybersecurity). 
GDPR constitutes a legal document seeking to unify and harmonize Member- States 
legislation with the objective to mitigate a concerning issue of the current time, data 
privacy, reforming an already obsolete directive7 (Directive 95/46 EC), proposed by the 
European Commission.   
 
                                               
4 Anna Jobin, Marcello Ienca & Effy Vayena, (02/09/ 2019), The global landscape of AI ethics guidelines,  
Nature Machine Intelligence ,volume 1, pages389–399 (2019), 
https://www.nature.com/articles/s42256-019-0088-2 
5Health Insurance Portability and Accountability Act (HIPAA)  
6 California Consumer Privacy Act of 2018 ( CCPA), effective into force on January 1, 2020, Assembly Bill 
No. 375 ,CHAPTER 55An act to add Title 1.81.5 (commencing with Section 1798.100) to Part 4 of Division 
3 of the Civil Code, relating to privacy.  
7 EUROPEAN DATA PROTECTION SUPERVISOR, The History of the General Data Protection Regulation : 
“It replaces the1995 Data Protection Directive which was adopted at a time when the internet was in its 
infancy”.(https://edps.europa.eu/data-protection/data-protection/legislation/history-general-data-
protection-regulation_en accessed online 11/10/2019). 
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CHAPTER A- General Data Protection Regulation (EU) 2016/679 
The European Commission on January 25, 2012,8 proposed the reforming of the legal 
framework within the EU borders, but also with extended territorial applicability, 
updating the rules applying to data privacy, a topic covered previously by the now 
outdated Directive 95/46/EC. 
The outcome of years in preparation9 was the General Data Protection Regulation 
(Regulation (EU) 2016/679 of the European Parliament and the Council), which came 
into full force on May 25th, 2018. The regulation10 litigates a number of prerequisites 
and obligations for organizations working within the EU or having any kind of activity 
inside EU borders, aiming to protect individuals and particularly employees, 
safeguarding their fundamental freedoms and rights, amongst them the right to 
privacy.11 
Part of the aforementioned legal reform constitutes the definition and specified 
protection for the processing of sensitive personal data12, health, genetic and 
biometric data. 
1. HEALTH DATA 
 Health data according to the GDPR, Article 4 §15, refer to the personal information 
regarding an individual’s mental or physical health including data and information 
provided by the health care system or services, in relation to the health status of the 
subject of these data.13 
 According to the European Court of justice the “data related to health” is 
regarded and interpreted in a broader scope, with the objective of the Court being that 
of including in its definition any possible personal information, both on the psychology 
and mentality and of the physiology of a person. Thus, even data regarding a previous 
injury of an individual can be perceived as sensitive personal information/data14.  
                                               
8EUROPEAN DATA PROTECTION SUPERVISOR The History of the General Data Protection Regulation : 
“EC proposal to strengthen online privacy rights and digital economyThe European Commission 
proposes a comprehensive reform of the EU's 1995 data protection rules to strengthen online privacy 
rights and boost Europe's digital economy.” (https://edps.europa.eu/data-protection/data-
protection/legislation/history-general-data-protection-regulation_en accessed online 11/10/2019). 
9 EUROPEAN DATA PROTECTION SUPERVISOR, The History of the General Data Protection Regulation : 
“In 2016, the EU adopted the General Data Protection Regulation (GDPR) … The timeline below contains 
key dates and events in the data protection reform process from 1995 to 2018”. 
(https://edps.europa.eu/data-protection/data-protection/legislation/history-general-data-protection-
regulation_en accessed online 11/10/2019). 
10 Stefanos Tsimikalis, 05/03/2019, GDPR & Employee Personal Data, by  Tsimikalis Kalonarou Law Firm, 
http://www.greeklawdigest.gr/topics/data-protection/item/314-gpdr-and-employee-personal-data 
accessed online 11/10/19).  
11 The Greek Constitution Article 9, Article 9A ( right to privacy) & ( right to protection of personal 
information, Article 2§1 (right to dignity) and Article 5 §1 (right to developing freely ones personality). 
12 Article 9 of the General Data Protection Regulation (EU) 2016/679.  
13 Article 4 §15 of the GDPR :data concerning health’ means personal data related to the physical or 
mental health of a natural person, including the provision of health care services, which reveal 
information about his or her health status;  
14 Case C101-01, Bodil Lindqvist, 6 November 2003. 
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 Pursuant to Recital 35 of the GDPR,15 there are a number of examples and 
cases where data concerning health can be perceived as such. For instance personal 
information entailed in this category, relating to the mental and physical health status 
of a person throughout their lifetime, constitute the following:  
 Collected information upon registering for receiving treatment or general 
health care services at an institution acting as a provider of such services (i.e. a 
hospital).16 
 Any identification number or symbolism or particular that is assigned to a 
natural person/ individual that can be used to identify them in a unique way in 
the context of health care. 
 Information that is extracted after performing tests and examinations upon a 
part of the human body or its substances, adding to it also genetic and 
biometric data.  
 Information of any kind relating to an illness, a disorder/ disability, disease risk, 
medical history, clinical treatment or the anatomical and biomedical status of 
an individual-subject of the personal data, regardless of the source from which 
they derive from, for instance, the health care system, a physician or a health/ 
medicine service provider and expert, even an in vitro diagnostic test. 
2. GENETIC DATA 
According to Article 4 (13) of the GDPR the definition given to the term “ 
Genetic data” is that of personal information regarding hereditary and acquired 
attributes of a natural person providing knowledge of a unique kind on one's 
physiology and health status, the product of an examination and analysis of a 
biological substance or particle of the data subjects body17.  
 The genetic information of the aforementioned nature can lead to the precise 
identification and differentiation of one individual from another. The DNA analysis is of 
the highest importance, as it could lead to the revelation of predisposition to diseases, 
from the data subject’s part, alongside the existence of inherited characteristics18. 
Thus, processing personal data of this nature should be met with the highest 
precautions, while performed with respect to the need for confidentiality and 
security19.  
                                               
15 Recital 35 of Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 
2016 on the protection of natural persons with regard to the processing of personal data on the free 
movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation- GDPR). 
16  Directive 2011/24/EU of the European Parliament and of the Council of 9 March 2011 on the 
application of patients’ rights in cross-border healthcare (OJ L 88, 4.4.2011, p. 45). 
17 Recital 34 of Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 
2016 on the protection of natural persons with regard to the processing of personal data on the free 
movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation- GDPR). 
18 Chara D. Zerva (Nicolas Kanellopoulos-Chara Zerva and Associates Law Firm Health),(2019), Biometric 
and Genetic Data Under GDPR, Greek Law Digest the official guide to Greek Law, 
http://www.greeklawdigest.gr/topics/data-protection/item/304-health-biometric-and-genetic-data-
under-gdpr  [Accessed Online on 20/10/2019]. 
19 Recital 39 of Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 
2016 on the protection of natural persons with regard to the processing of personal data on the free 
movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation- GDPR). 
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3. BIOMETRIC DATA 
 Article 4 (14) of the GDPR states that “Biometric data” are: “personal data 
resulting from specific technical processing relating to the physical, physiological or 
behavioral characteristics of a natural person, which allow or confirm the unique 
identification of that natural person, such as facial images or dactyloscopy data”. The 
Regulation broadens the scope of biometric data’s definition with this provision in 
order to render it applicable to both existent and possible techniques of processing 
biometric information in the foreseeable future.20 
 Biometric information when processed can result in the identification and/or 
the authentication/verification of the data subject, through the use of biometric 
technological applications, such as biometric systems. This kind of systematic 
processing is based upon traits of three particular kinds:21 
1. Universal traits, all individuals possess such biometric characteristics 
2. Unique traits can be in relation to one particular individual only.  
3. Permanent traits, biometric elements that remain stable and unchanged in one 
individual through time. 
Biometric techniques can be further devised into – now three22- categories in 
relation to the kind of characteristics they are based on: 
1. Physiological characteristics such as fingerprint analysis and identification/ 
verification, iris & face recognition, retina analysis, voice recognition, DNA 
analysis, etc. 
2. Behavioral-based analysis, opting in the measuring and collection of signs of 
the behavior of a certain individual such as signature in handwriting 
pattern, gait analysis, particular walking movement, subconscious mentality 
in patterns, like lying, etc. 
3. Psychological attributes that an evolving biometric technique is relying 
upon in order to measure a person’s particular reactions to certain events 
and tests so as to draw psychological profiles from.  
 
3.1 Processing sensitive data 
  
Pursuant to Article 5 (1) and Article 9 of the GDPR, health, genetic and biometric data 
constitute a set of sensitive data, as per the prior legislative framework, but also a 
special category of personal data, demanding a higher level of transparency, fairness, 
                                               
20 Chara D. Zerva (Nicolas Kanellopoulos-Chara Zerva and Associates Law Firm Health),(2019), Biometric 
and Genetic Data Under GDPR, Greek Law Digest the official guide to Greek Law, 
http://www.greeklawdigest.gr/topics/data-protection/item/304-health-biometric-and-genetic-data-
under-gdpr  [Accessed Online on 20/10/2019]. 
21 ARTICLE 29 - Data Protection Working Party, Working document on biometrics  
, Adopted on 1 August 2003, 12168/02/EN 
WP 80. 
22 ARTICLE 29 DATA PROTECTION WORKING PARTY, Opinion 3/2012 on developments in biometric 
technologies, 00720/12/EN 
WP193. 
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and protection, as far as it comes to their processing.23 One of the basic principles laid 
out on Article 5 (1b) relates to the purpose limitation principle24, meaning that data 
shall be collected and processed pursuant to the original objective for which they were 
stored and the procedure of their analysis will not deviate from the purpose that it was 
initiated for. Broader flexibility and freedom have been appointed to the achievement 
of purposes regarding the public interest, science, history or research in general, but in 
accordance to Article 89, introducing allowance to processing only when safeguarding 
of the rights and freedoms of the data subjects is secured and offered (Article 9 §.2).  
 Processing, according to Article 4 (2) of the GDPR: “processing’ means any 
operation or set of operations which is performed on personal data or on sets of 
personal data, whether or not by automated means, such as collection, recording, 
organization, structuring, storage, adaptation or alteration, retrieval, consultation, use, 
disclosure by transmission, dissemination or otherwise making available, alignment or 
combination, restriction, erasure or destruction”; 
Sensitive data/ Special category of data: information that can reveal the racial 
or ethnic origin of a person, political, religious or philosophical mindset or beliefs, 
trade union membership and the newly added, in Article 9 (1) of the GDPR, the genetic 
and biometric data that can lead to the identification of a person, data concerning 
their health, gender, sex life or sexual orientation. All the above-mentioned categories 
of data cannot be processed unless specific legal conditions are met set by the same 
article.25  
Namely they include, but are not limited to: a) explicit consent by the data 
subject, unless the Member state’s or the Union’s relating existent provisions do not 
allow for the lifting of the aforementioned prohibition, even by the subject’s 
consensual agreement, b) it is vital for the fulfillment of obligations or exercising of 
rights both of the controller and of the data subject in the employment and social 
security sector and social protection law, under the authorization of Union or Member 
State law or relative agreement provided again that the necessary safeguards for the 
fundamental rights and interests of the data subject are being offered, c) for the 
protection of the data subject’s interests or of another person’s when the subject is 
physically unable or legally incapable of giving their consent, d) they have been 
manifestly made public by the data subject, e) there needs to be a processing of 
sensitive data for the purposes of preventive and occupational medicine, for assessing 
the working potency of an employee, for purposes of medical diagnosis, the providing 
of health or social care or treatment, the managing of health or social care systems or 
services based on Union or Member State law, in accordance with a contract with a 
health professional but also subjected to the following conditions.26 
In Paragraph 3 of Article 9 of the GDPR, the regulation stresses that the lifting 
of the processing prohibition can only be valid while the said processing is performed 
                                               
23 Recital 51 of Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 
2016 on the protection of natural persons with regard to the processing of personal data on the free 
movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation- GDPR). 
24 Article 5 (1b) of the GDPR: collected for specified, explicit and legitimate purposes… not be considered 
to be incompatible with the initial purposes (‘purpose limitation’); 
25 Article 9 par. 2 of the GDPR. 
26 Recital 53 of Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 
2016 on the protection of natural persons with regard to the processing of personal data on the free 
movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation- GDPR). 
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by a health care professional subject to the obligation of professional secrecy, 
pursuant to Union or Member State law or provisions set into force by competent 
bodies or another individual also subject to the above mentioned legal framework. 
Last but not least, a novelty introduced by the GDPR, with the aim to further 
facilitate and not impede research, is the concept of broad consent. Even though not 
explicitly stated with in the Regulation, broad consent as an option when processing 
personal data for research purposes is apparent from the combination of Article 727  
and Recital 3328 of the GDPR. According to these, the regulation acknowledges the fact 
that the exact purposes of a research might not be possible to be fully explained from 
its beginning, thus they provide with the solution for the data subject to provide 
consent to the general area of the research. More specifically, the data subject can 
give its consent to certain parts of the research, only to certain parts of the research or 
to parts of a particular research project.29 However, even in this case in order to 
provide with the necessary protection, the researcher should acquire this form of 
consent after sufficiently informing the data subject about the research and after they 
have also acquired a clear and unambiguous indication of the data subject’s desire to 
have their data processed during the research project. An issue, although could occur, 
in relation to a certain contradiction between the recital and the actual articles ( 7 and 
9). The Regulation, actually, stresses the need for “recognized ethical standards for 
scientific research” to be upheld, in order for broad consent to be lawful, when on the 
same time the derogations for research purposes permitted by the legal text might not 
be compatible with these ethical standards.30 
3.2 Derogations 
 In accordance with Article 9 (4)31 of the General Data Protection Regulation 
Member States can introduce deviations, entertaining stricter measures, from the 
above conditions for processing special category personal data, including health, 
genetic and biometric data. However, on Recital 53 -relating to the processing of 
Sensitive data on Health and Social sector, it is highlighted that such limitations should 
not impede the liberal exchange and flow of data within the Union and amongst the 
                                               
27 Article 7 of the Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 
2016 on the protection of natural persons with regard to the processing of personal data on the free 
movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation- GDPR).  
28 Recital 33 of Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 
2016 on the protection of natural persons with regard to the processing of personal data on the free 
movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation- GDPR), 
“It is often not possible to fully identify the purpose of personal data processing for scientific research 
purposes at the time of data collection. 2Therefore, data subjects should be allowed to give their 
consent to certain areas of scientific research when in keeping with recognised ethical standards for 
scientific research. 3Data subjects should have the opportunity to give their consent only to certain 
areas of research or parts of research projects to the extent allowed by the intended purpose.”  
29 Health Research Board, GDPR Guidance for Researchers, Broad Consent, 
https://www.hrb.ie/funding/gdpr-guidance-for-researchers/gdpr-and-health-research/consent/broad-
consent/ (online) accessed 06 Dec 19. 
30 Staunton, C., Slokenberga, S. & Mascalzoni, D. (2019), The GDPR and the research exemption: 
considerations on the necessary safeguards for research biobanks. Eur J Hum Genet 27, 1159–1167 
doi:10.1038/s41431-019-0386-5  
31 Article 9 (4), GDPR: “Member States may maintain or introduce further conditions, including 
limitations, with regard to the processing of genetic data, biometric data or data concerning health.” 
 -10- 
Member States when they could be applicable to cross-border processing of such kind 
of data. In this context, Member States could deviate from the initial restrictions on 
processing sensitive data, while at the same time they need to be providing with the 
relative safeguards and protections of the fundamental right and interests of the data 
subjects.  
 Making use of this provision, the German Data Protection Law32 allows for the 
processing of sensitive personal data in certain cases, without the consent of the data 
subject, when such processing is vital for the procurement of preventive medicine, 
when it is crucial for the determination of the working capacity of an employee, along 
with the securing of the superiority of the quality of the health care industry and 
medicinal products and services. Moreover, the UK Data Protection Act 201833 
introduces clauses with limitations on the implementation of the GDPR’s provisions – 
pursuant to Article 23 (1) of the GDPR and the ability to restrict rights and obligations 
that it includes- that is in relation to health care, such as the processing of data by 
health care professionals in order to provide medical services. 
4. Prior Legislation 
The previous legal framework for the protection of personal data and of special 
categories of data, within the Union, constitute the Directive 95/46/ EC34 (hereinafter 
the Directive) of the European Parliament and of the Council, an effort to ensure lawful 
protection of an individual’s privacy in relation to new technologies. Although, as 
innovation in the technological sector begun to escalate beyond the existent scope of 
the Directive, the European Commission on 2009 launched the endeavour of the 
reformation of the Directive, trying to update the existent provisions, rendering them 
more contemporary and appropriate to the emerging needs of the modern reality, but 
also providing with a higher level of harmonization, through the establishment of a 
Regulation – the GDPR – instead of a Directive that had to be further implemented by 
27 Member States, a legal document of direct force to every Member State.35  
 The Directive presented with several differences upon comparison with the 
Regulation. Even if there was a reference to personal data and their definition along 
with a definition for sensitive personal data as a separate category of the data 
subject’s information, there was no direct reference in the Articles of biometric and 
genetic data, even though health data were included in the scope of the Directive and 
demanded for special conditions for processing, pursuant to Article 836. However, in 
the GDPR there is an explicit reference of the term “genetic”, for providing with a 
                                               
32 Art. 22 of the German Federal Data Protection Act (BDSG). 
33 Schedule 3 of the UK Data Protection Act (2018).  
34 Directive 95/46/EC of the European Parliament and of the Council of 24 October 1995 on the 
protection of individuals with regard to the processing of personal data and on the free movement of 
such data, Official Journal L 281 , 23/11/1995 P. 0031 – 0050. 
35 Mahsa Shabani & Pascal Borry, (2017), Rules for processing genetic data for research purposes in 
view of the new EU General Data Protection Regulation, European Journal of Human Geneticsvolume 
26, pages149–156 (2018), https://www.nature.com/articles/s41431-017-0045-7 [ Accessed Online on 
20/05/2019]. 
36 Article 8 of  Directive 95/47/ EC : The processing of special categories of data “ Member States shall 
prohibit the processing of personal data revealing racial or ethnic origin, political opinions, religious or 
philosophical beliefs, trade-union membership, and the processing of data concerning health or sex 
life.”  
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definition of personal data- is Article 4(1), but also in Article 937 it explicitly includes in 
the category of sensitive personal information biometric and genetic data ( while on 
the same time providing with definitions of such kind of data, as seen above).  
 All things aside, the new Regulation follows the general principles laid by its 
predecessor, the Directive, adding though some novel provisions and revisions, but not 
in all subjects. Regarding the issue of the distinction between the anonymous and the 
anonymized data38, the Regulation, as the Directive before it, fails to provide a 
clarification relating to these deferent kinds of data, while it explains the scope of 
personal data on Recital 2639. Anonymization, according to Article 29 Working party 
could be considered further processing of the already collected in an identifiable way 
set of data40. On the contrary, the Regulation included in its provisions a definition for 
pseudonymization, a provision lacking from the Directives framework. Pursuant to 
Article 4(5) pseudonymized data are those data that cannot be credited to a data 
subject without the use of supplementary information, kept within the relevant 
safeguards for ensuring the inability to be related to an identifying of an identifiable 
natural person. According to Recital 26 of the Regulation, this kind of data can be 
regarded as personal data if by “all means reasonably likely to be used” they can be 
lead to the identification of the data subject, the original source of the pseudonymized 
data. In the same context and pursuant to the proportionality principle, depending on 
the likelihood of such an event to occur the conditions and limitations of the 
Regulation shall apply with an accordingly equal and proportionate flexibility to this 
kind of data.41  
5. National Legislations 
The GDPR, despite its legal scope and nature as a regulation (of immediate 
application to the Member States’ legal system), entails several clauses that allow to 
the national legislator to deviate from the legislation’s scope, including the chapter 
                                               
37 Article 9 of the GDPR: Processing of special categories of personal data “Processing of personal data 
revealing racial or ethnic origin, political opinions, religious or philosophical beliefs, or trade union 
membership, and the processing of genetic data, biometric data for the purpose of uniquely identifying 
a natural person, data concerning health or data concerning a natural person’s sex life or sexual 
orientation shall be prohibited.” 
38 Beyleveld D, Townend D. When is personal data rendered anonymous? Interpreting recital 26 of 
Directive 95/46/EC. Med Law Int. 2004;6:73–86. 
39 Recital 26 of Directive 95/46/ EC: “Whereas the principles of protection must apply to any 
information concerning an identified or identifiable person; whereas, to determine whether a person is 
identifiable, account should be taken of all the means likely reasonably to be used either by the 
controller or by any other person to identify 
the said person; whereas the principles of protection shall not apply to data rendered 
anonymous in such a way that the data subject is no longer identifiable; whereas codes of conduct 
within the meaning of Article 27 may be a useful instrument for providing guidance as to the ways in 
which data may be rendered anonymous and retained in a form in which identification of the data 
subject is no longer possible;”. 
40 Article 29 WP: “Anonymization constitutes a further processing of personal data; as such, it must 
satisfy the requirement of compatibility by having regard to the legal grounds and circumstances of the 
further processing”. 
41 Article 29 Working Party. Opinion 4/2007 on the concept of PersonalData, 2007.  
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relating to processing sensitive data, such the aforementioned ones.42 The Greek Law 
in implementation of the Regulation is Law 4624/2019.  
 Pursuant to the above right of legislating according to national standards and 
particular circumstances Article 30 introduces exceptions to the general prohibition of 
Article 9 of the GDPR regarding the possibility of processing for statistical or public 
interest or for scientific and historical research purposes. However, the exceptions are 
only permitted if they are in accordance with Article 89, which states, along with 
Article 9§2, that specific measures need to be taken in order to safeguard the rights of 
the data subject in interest. The Greek Law makes no such remarks, apart from those 
already existing within the framework and text of the Regulation (e.g. 
pseudonymization43).  
  Contrary to the recent legal provision, the previous legislation44, which 
incorporated the Directive 95/46/EC in the national legal system, followed its example 
regarding the general prohibition of processing sensitive data (Art.8 95/46/EC). At the 
same time, though, it allowed processing by associating its legality not only with the 
existence of specific and substantial reasons for it but also by the acquiring of a permit 
from the National Data Protection Authority (Art. 7 Law 2472/1997). 
  In additional contradiction to the vagueness of the newly established legal 
scope in Greece, the German legislation with the Federal Data Protection Act45, 
provides with a detailed list of measures to be applied so as to ensure the protection 
of fundamental rights of the data subject, such as but not limited to: a) “measures to 
ensure that it is subsequently possible to verify and establish whether and by whom 
personal data were input, altered or removed b) measures to increase awareness of 
staff involved in processing operations and c) measures to ensure the ability, 
confidentiality, integrity, availability and resilience of processing systems and services 
related to the processing of personal data, including the ability to rapidly restore 
availability and access in the event of a physical or technical incident” (Federal Data 
Protection Act of 30 June 2017 (Federal Law Gazette I p. 2097). Last but not least, in 
the same more specific nature, the Austrian law, implementing GDPR principles, 
provides a detailed course of action in order to enact the clause that lifts the exception 
in processing, which is correlated with the procurement of a permit from the Data 
Protection Authority. In fact, in the legal text, it is even explained thoroughly the 
process and the criteria on which the decision of the Authority will be based upon.46 
 Moreover, in the United Kingdom the Data Protection Act,2018 (henceforth 
DPA), also makes use of the potential exemption from the prohibition of processing 
sensitive personal data, on several grounds and upon meeting the lawful conditions. 
Amongst them there is also the condition reserved for archive, historic and research 
purposes, which does not appear to be introduced with any changes, in the national 
legislation (or with any specified provisions, apart from pseudonymization)47. A novelty 
constitutes, the provision relating to processing for employment, social security and 
                                               
42 L.Mitrou, The General Data Protection Regulation, Athens 2017, pp.25 etc. 
43 Art. 89 §1 , GDPR 
44 Law 2472/1997. 
45 Federal Data Protection Act of 30 June 2017 (Federal Law Gazette I p. 2097, (BDSG) , Sub-chapter 1, 
Section 22§2 and Sub-chapter 2, Section  27. 
46 Federal Act concerning the Protection of Personal Data (DSG), Part 2 §2 & §3.  
47 Schedule 1, Part 1, paragraph 4 DPA. 
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social protection purposes, which is allowed provided that there is an appropriate data 
policy document drafted, stating the data controller’s procedure for ensuring the 
compliance with principles in Article 5 of the GDPR.48 Another novelty introduced is 
the change in the age limit of consent in the case of minors. According to the GDPR, 
the age limit is 16 years but pursuant to the DPA is now 13 years.49  
6. US Legislation  
The US has to display not a concrete base of one federal law ruling over the 
issue of data privacy, in relation to health, biometric and genetic data, but a 
combination of both federal laws and state laws, which protect Americans to different 
extents. 
 First and foremost, chronologically and in a federal scope, there is the Health 
Insurance Portability and Accountability Act (HIPAA)50, which provides a specified set 
of described entities and collections of data that are regulated in its framework 
(Protected Health Information (PHI). Notwithstanding the efficacy and adequacy of the 
level of HIPPA’s protection there is an issue with the extent of that same protection as 
only “covered entities” and “ associated business” fall under its scope. Thus, the 
majority of well-known data minors, such as Google and Amazon which deal with huge 
amounts of data and some of them health-related, are usually excluded from this legal 
framework.51 In addition, HIPPA protects information that can lead to the 
identification of a person (part 160 & 164), leaving any information rendered 
unidentifiable outside the law’s protective provisions. Such kinds of de-identified data 
can occur in two ways according to HIPPA: a) by striking out designated in the law 
identifying information and b) by acquiring estimation from an expert in statistics 
confirming the significantly low risk of re-identification. However, both ways have 
been found to be rather inadequate52 in practice, particularly in the case of genetic 
data and information, usually de-identified, but only to a minimum extent, so as avoid 
applicability of HIPPA, when actually information that could lead to the re-
identification of the data subject are frequently kept and up for exchange by the so-
called data minors (e.g. doctor’s names, case number’s, dates)53  
 Moreover, another federal legislation aiming at enriching the level of 
protection, this time relating to genetic information, is The Genetic Information Non-
discrimination Act, Public Law 110-223 (GINA). GINA constitutes a means for 
prohibiting discrimination in the Insurance (I)54and the Employment (II)55 sector. 
                                               
48 Schedule 1, Part 1, paragraph 1 DPA, Schedule 1, Part 4, paragraph 39 DPA. 
49 Part 2, Chapter 2, Section 9 DPA. 
50 The Health Insurance Portability and Accountability Act of 1996 (HIPAA). P.L. No. 104-191, 110 Stat. 
1938 (1996). 
51 A. Tanner, Strengthening Protection of Patient Medical Data The Century Foundation (2017), 
https://tcf.org/content/report/strengthening-protection-patient-medical-data , accessed 26/11/19) 
52 K. Benitez and B. Malin, Evaluating Re-identification Risks With Respect to the HIPAA Privacy Rule, 17 
J. am. med. inform. assoc. 169, 177 (2010). 
53 J. Kulynych and Henry T. Greely, Clinical Genomics, Big Data, and Electronic Medical Records: 
Reconciling Patient Rights With Research When Privacy and Science Collide, 4 J. law. biosci. 94, 132, 122 
(2017). 
54 TITLE I—GENETIC NONDISCRIMINATION IN HEALTH INSURANCE, GINA 2008.  
55 TITLE II—PROHIBITING EMPLOYMENT DISCRIMINATION ON THE BASIS OF GENETIC INFORMATION, 
GINA 2008. 
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Americans are protected from having their genetic information used by the above 
parties to hamper their access to beneficial insurance contracts (e.g. regardless of their 
genetic condition) and to fair employment offers. This framework includes family 
medical history, not undergoing genetic testing upon request, the results and 
information relating to similar tests already taken, all applicable to both the private 
and the public sector.56 More specifically, GINA incorporates provisions that affect the 
participants of clinical research with an emphasis on informed consent and how and 
what grounds it should be acquired upon.57 What GINA does not regulate are 
companies that fall under its exception by having less than 15 employees, long-term 
care insurance, life insurance or disability insurance. Furthermore, GINA provides a 
definition of genetic testing, as the analysis of DNA, RNA chromosomes, proteins or 
metabolites aiming at the detection of genotypes, mutations, or chromosomal 
changes. Any other kind of testing (e.g. enzyme tests) is not considered as genetic tests 
under the protection scope of GINA. Genetic tests of proteins and metabolites that are 
associated with the manifestation of diseases and disorders are not considered genetic 
testing under GINA as well.58 
On a state level several efforts have been set in place from states such as the 
State of California (California Consumer Privacy Act, CCPA), the state of Illinois (2008 
Illinois Biometric Information Privacy Act (BIPA) and the ruling of January 2019 on the 
Rosenbach v. Six Flags case) and the San Francisco’s Board of Supervisors anti-
surveillance ordinance (May 2019). 
California Consumer Privacy Act (CCPA)59 passed on the 25th of January 2019 
and will be effective from January 2020. It provides the protection of rights to privacy 
of the citizens of California, focusing on consumer protection, but in relation to the 
collection of biometric data. Its definition of the latter set of data appears broader 
than the one given in the GDPR: “an individual’s physiological, biological or behavioral 
characteristics, including an individual’s DNA that can be used, singly or in combination 
with each other or with other identifying data, to establish individual identity.”60 
According to the ruling of the Supreme Court of Illinois in the case of 
Rosenbach v. Six Flags case61, the Illinois Biometric Information Privacy Act (BIPA)62 
provides with the right to take action brought before the court without the need of 
claiming additional harm, just the absence of an opt-in consent for the collection of 
biometric data, such as fingerprint and face recognition data. 
 
                                               
56 ‘Genetic Information Non-discrimination Act, PUBLIC LAW 110–233—MAY 21, 2008,  
57 A description of any reasonably foreseeable risks or discomforts to the subjects (45 CFR 46.116(a)(2)); 
and A statement describing the extent, if any, to which confidentiality of records identifying the subject 
will be maintained (45 CFR 46.116(a)(5), GINA, 2008.  
58 Human Research Protection, Genetic Information Nondiscrimination Act Guidance (2009), March 24, 
2009.  
59 Assembly Bill No. 375, California Consumer Privacy Act, Date Published:06/29/2018. 
60 LAURA JEHL AND ALAN FRIEL, BAKERHOSTETLER LLP, A Chart comparing some of the key 
requirements of the California Consumer Privacy Act (CCPA) and the EU General Data Protection 
Regulation (GDPR), https://www.bakerlaw.com/webfiles/Privacy/2018/Articles/CCPA-GDPR-Chart.pdf , 
(Online), accessed on: 26 Nov. 19.  
61 Rosenbach v. Six Flags Entertainment Corp., 2019 IL 123186, Supreme Court, 25th of January.   
62 740 ILCS 14/ Biometric Information Privacy Act. 
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San Francisco’s Board of Supervisors'63 anti-surveillance ordinance (May 2019) 
ruled against the use of facial recognition technology from major representatives of 
the public sector and law enforcement (e.g. police, governmental bodies). 
 
 
CHAPTER B- NEW TECHNOLOGIES 
New technologies have brought groundbreaking changes in the lives of billions 
worldwide since the beginning of the century. Now more than ever, computational 
and informational technology alongside cutting-edge research on the field of data 
analysis the potential to bring upon revolutionary possibilities in the health care 
sector.  
From direct to consumer genetic testing, overcoming the legal impediments 
and procuring the public with a ready to use time capsule and by its evolution as 
service a lot more than that, to the mobile health applications (hence fort apps), with 
their portable nature providing access to biometric data, health status analysis and 
indispensable aid to those in need (e.g. mental health care apps). 
Last but not least, Artificial Intelligence (henceforth AI) technology and 
innovation has offered the opportunity to collect, combine and analyze a very large 
amount of data (big data analysis), while at the same time resulting in comprehensive 
conclusions able to promote the advancement of medical studies even further, to 
disease prevention, precision medicine, epidemiological analysis and the accelerating 
of medical procedures in general.  
However, the progress made on a scientific level demonstrates not only the 
potential of mankind but also its obligation to synchronize the current legislation and 
ethical conversation with the demands of the modern era. Technology constitutes a 
tool that, like any other, can be misused without proper guidance. 
 
 
1. DIRECT TO CONSUMER GENETIC TESTING/ GENETIC DATA 
 
1.1 The US. 
 
The technological revolution of genome sequencing has brought incredibly 
rapid changes in the ability to sequence a large amount of genetic data in a faster, 
cost-effective and accurate way. Next-generation sequencing with its potential to map 
the entire genome of a person with unprecedented quality and velocity opened up 
new possibilities to the scientific community, the pharmaceutical industry, the public 
sector, and various biotechnological companies, now enabled to draw information 
from the largest pool of big data ever available to researchers.  
Direct- to- consumer genetic testing (DTC) is the product of such advancement, 
made possible by the increasing affordability of genome sequencing, accompanied 
                                               
63 Stop Secret Surveillance Ordinance (05/06/2019), Board of Supervisors. 
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though with its respective legal challenges, as health information is being more and 
more directed outside the public care sector and into the private commercial initiative.  
The U.s Food and Drug Administration has had a leading role in the regulatory effort 
related to this emerging genetic testing device, moving from the more traditional 
“Protective” Medical Device approach to adopting, after taking under consideration 
the Consumer-Based “Libertarian” Critique, a more hybrid and flexible position. This 
final aspect was highlighted by its licensing to the well-known company 23andMe to 
provide medical information relating to the potential of its clients to have disease risk 
factors in their DNA (Genetic Health Risk Test).64  
The more traditional “Protective” Medical Device prototype derived from the 
FDA’s jurisdiction to regulate any medical device under the scope of the Federal Food, 
Drug and Cosmetic Act (FDCA), with a general description as: “an instrument, 
apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar 
or related article ...which is ... intended for use in the diagnosis of a disease or other 
conditions or in the cure, mitigation, treatment, or prevention of disease."65 In 
addition, medical devices are classified into 3 separated categories related to their 
high, moderate or low-risk factors, according to the 1976 Medical Device Amendments 
(MDA) to the FDCA.66  In the context of this framework there is a description provided 
of in vitro diagnostics (IVDs), in contradiction to Laboratory Developed Tests (LDTs), 
IVDs constitute: “Those reagents, instruments, and systems intended for use in the 
diagnosis of disease or other conditions, including a determination of the state of 
health, in order to cure, mitigate, treat, or prevent disease or its sequelae. Such 
products are intended for use in the collection, preparation, and examination of 
specimens taken from the human body.”67 Those kinds of tests are available for 
distribution to hospitals, clinics and directly to patients, while on the contrary LDTs are 
meant for research purposes only. As a result, the FDA has made clear that the Direct-
to-Consumer testing does not fall under the scope of the latter, but instead its 
manufacturers have to inform the FDA prior to market release, and do not partake in 
the regulatory exception of the LTD.68 
A more liberal approach to the matter has been brought forward by 
stakeholders and the scientific community, relating to the lack of flexibility and 
acceptance from the FDA’s and the traditional medical care professionals’ part. 
Unwilling to embrace the innovative steps to bring health information in the hands of 
the patients, based upon them losing their traditional role as key facilitators of the 
process, they appear to be impeding the progress of informational technology, 
hampering the rights of the consumers. Consequently, FDA revised its course of action 
                                               
64 Sharkey, C. M. (2019). Direct-to-consumer genetic testing: The fda's dual role as safety and health 
information regulator. DePaul Law Review, 68(2), 343-384. 
https://heinonline.org/HOL/Page?collection=journals&handle=hein.journals/deplr68&id=372&men_tab
=srchresults# ( online) accessed: 20 Nov.2019).   
65 21 U.S.C. § 321(h), (h)(2) (2012). 
66 21 U.S.C. § 360c(a)(1)(C)(ii)(I)-(II) (2012). 
67 21 C.F.R. § 809.3 (2018), Overview of IVD Regulation, U.S. FOOD & DRUG ADNMwN., 
https://www.fda.gov/MedicalDevices[DeviceRegulationandGuidance/IVDRegulatoryAssistance (online) 
accessed : 20 Nov.19.  
68 Nancy K. Stade et al., FDA Challenges Direct-to-Consumer Genetic Tests, 
LAw360 (Mar. 22, 2016, 11:47 AM), https://www.1aw360.com/articles/772679/fda-challenges-direct-
to-consumer-genetic-tests. (Online) accessed: 20 Nov. 19.  
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by introducing 2012 Food and Drug Safety and Innovation Act and its fast-forward “de-
novo” process of filling for the approval of the Administration69, in combination with 
the authorization of Genetic Health Risk (GHR) tests in the market since 2017 
(23andMe included)70.   
 
 
1.2 EU. 
 
At the moment there is not one specific regulatory framework within the EU 
that applies to the DTC genetic testing, but the provisions of several other legal 
instruments and documents can be used to provide a level of protection and guidance 
to this innovative tool. 
Firstly, there is the Unfair Commercial Practices Directive 2005/29 EC71 
regarding the protection of consumers from misleading actions and omissions but also 
from the use of technics from the traders’ part that results in psychological pressure or 
deception in the advertisement72. Moreover, this kind of genetic testing is considered 
an IVD medical device, as seen above from the US regulation, meaning that it is subject 
to stricter conditions than other products. That is precisely depicted within the scope 
of Directive 93/42/EEC73 concerning medical devices and Directive 98/79 EC on In Vitro 
Diagnostic Medical Devices74, which provides with the provisions related to the level of 
safety and efficiency requirements those devices need to meet before they can be 
approved for the European Market.  
 
Apart from the regulated aspect of DTCs as products, there is also a side of 
them that can not fit into the above framework and can be more accurately appointed 
to the healthcare service context (e.g. genetic counseling, rules of informed consent ). 
As the healthcare services in relation to genetic testing has not been regulated as a 
                                               
69 U.S. FOOD & DRUG ADMIN., FDA-2011-D-0577, GUIDANCE FOR INDUSTRY AND FOOD AND DRUG 
ADMINISTRATION STAFF: FACTORS TO CONSIDER WHEN MAKING BENEFIT-RISK DETERMINATIONS IN 
MEDICAL DEVICE PREMARKET APPROVAL AND DE Novo CLASSIFICATIONS 4 (2016) 
https://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/
UCM517504.pdf (online),  accessed: 20 Nov.2019.  
70 Press Release, U.S. Food & Drug Admin., Statement from FDA Commissioner Scott 
Gottlieb, M.D., on Implementation of Agency's Streamlined Development and Review Pathway for 
Consumer Tests That Evaluate Genetic Health Risk (Nov. 6, 2017), 
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm583885.htm.(online), 
accessed: 20 Nov.2019.  
71 European Parliament and the Council of the EU (2005) Directive 2005/29/EC of the European 
Parliament and of the Council of 11 May 2005 Concerning unfair business-to-consumer commercial 
practices in the internal market and amending council directive 84/450/EEC, directives 97/7/EC, 
98/27/EC and 2002/65/EC of (2005).  
72 European Commission (2016) The Black List: banned commercial practices - European Commission – 
DGhttp://ec.europa.eu/justice/consumer-marketing/unfair-trade/unfair-practices/is-it-
fair/blacklist/index_en.htm (online), accessed: 22 Nov.2019.  
73 COUNCIL DIRECTIVE 93/42/EEC of 14 June 1993 concerning medical devices (OJ L 169, 12.7.1993, p. 1) 
74 European Parliament and Council (1998) Directive 98/79/EC of the European Parliament and of the 
Council of 27 October 1998 on in vitro diagnostic medical 
devices.http://eurlex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:31998L0079:EN:HTML (online), 
accessed: 22 Nov.19. 
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whole by the EU and usually it is left for the Member States to decide, this legal 
practice leaves enough space for the national legislators to step in and establish their 
own regulation on a national level, which varies from one jurisdiction to another.75 
However, coalition and accordance with international legal documents should 
be established, such as the Convention on Human Rights and Biomedicine (Oviedo 
Convention)76 of the Council of Europe and its Additional Protocol on Genetic Testing 
for Health Purposes77. The Convention together with the Additional Protocol, ratified 
and now into force, touch upon topics such as human dignity and fundamental 
principles for medical practice (e.g. informed consent) but also specific aspects of the 
context of genetic testing, like medical supervision and genetic counseling. 78 
 
 
2. MOBILE HEALTH APPLICATIONS/ BIOMETRIC DATA 
 
 According to the World Health Organisation Mobile Health (henceforth “m-
health”) constitutes: “medical and public health practice supported by mobile devices, 
such as mobile phones, patient monitoring devices, personal digital assistants (PDAs), 
and other wireless devices”79 Adding to this new term, there are also lifestyle and well-
being applications, that provide with a variety of information, relating to the 
connection of sensors and the produced biometric data. Their existence is based on an 
alternate offer of guidance and the increase of involvement of the public in their own 
quality of life but also the raising of awareness and promotion of preventive 
approaches relating to the health status of individuals.80 
 
Alongside the numerous potentials of the procurement of such an empowering choice 
and tool to the public, there are several issues and challenges that need to be tackled, 
one of the primary ones being the issue of privacy. A major concern of consumers 
relate to the sharing of the data from m-health applications to third parties (e.g 
employers, insurance companies), which is proven by the results of a study indicating 
                                               
75 Godard B, Kääriäinen H, Kristoffersson U, Tranebjaerg L, Coviello D, Aymé S (2003) Provision of 
genetic services in Europe: current practices and issues. Eur J Hum Genet 11(S2):S13–S48.  
https://doi.org/10.1038/sj.ejhg.5201111 (online), accessed: 22 Nov.19  
76 Council of Europe (1997) Convention for the Protection of Human Rights and Dignity of the Human 
Being with regard to the Application of Biology and Medicine: Convention on Human Rights and 
Biomedicine. Council of Europe, Oviedo, 4.I.V.1997.  
77 Council of Europe (2008). Additional Protocol to the Convention on Human Rights and Biomedicine, 
concerning Genetic Testing for Health Purposes., 01/07/2018- 5 Ratifications including 4 member States. 
https://www.coe.int/en/web/conventions/full-list/-/conventions/treaty/203 (online), accessed: 22 
Nov.2019. 
78 Kalokairinou, L., Howard, H.C., Slokenberga, S. et al. J Community Genet (2018) 9: 117. 
https://doi.org/10.1007/s12687-017-0344-2 (online), accessed: 22 Nov.19.  
79 World Health Organisation “mHealth – New horizons for health through mobile technologies, Global 
Observatory for eHealth series – Volume 3”, page 6 
80 EU Commission’s GREEN PAPER on mobile Health ("mHealth"),COM(2014)219 10.4.2014, final. 
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that 45% of consumers share such a concern about the unwanted use of their data, in 
the context of using m-health applications.81 
 The increased concern is logically met with relevant protective measures from 
the EU’s side. In fact, in Article 8 of the Charter of Fundamental Rights of the European 
Union, as well as in Article 16(1) of the Treaty on the Functioning of the European 
Union (TFEU), there is an establishment of the right to the protection of personal data. 
Pursuant to the fundamental nature of the above-mentioned provision the EU 
demands compliance with the applicable provisions deriving from the GDPR (especially 
principles applying to processing sensitive data and the opt-in & opt-out rights).  
Furthermore, issues might occur depending on which scope each m-health application 
best fits in to. More specifically, judging from the nature of each application, ad hoc, 
manufacturers might find their products falling either within the scope of the Medical 
Devices Directive (Directive 93/42/EEC) or In vitro diagnostic medical devices Directive 
(Directive 98/79 EC). To that extent the Green Paper on m-health from the European 
Commission is accompanied by the Staff Working Document on the existing EU legal 
framework applicable to lifestyle and wellbeing apps, aiming to offer guidance upon 
the legal framework related to the m-health apps.82 
In association with data privacy and security there comes also the need for 
safety and efficiency relating to the content of each m-health app, meaning its 
function and trustworthiness. To that end, several standards of safety must be met, 
which can be proven through the acquiring of certifications. Such kind of programs and 
initiatives are, amongst others, the National Health Service83, an online Health Apps 
library in the United Kingdom, the Happtique in the US84, a specialized platform for 
selling certified health apps and the European Directory of Health Apps85, striving for 
the transparency and reliability of the recommended health apps.  
 
  2.1 Regulated & Unregulated Cases 
 
On the other hand, there is the issue of m-health applications from a more medical 
and sensitive point of view as it appears that an increasing number of consumers opt 
for such technological services in order to deal with mental health problems. Indeed, 
more than 10,000 available apps today regard mental health86 when the number of 
downloads of this kind of applications has doubled in 2016, according to statistic 
                                               
81 Blue Chip Patient Recruitment. Leveraging Mobile Health Technology for Patient Recruitment, 
October 2012 
82 COMMISSION STAFF WORKING DOCUMENT on the existing EU legal framework applicable to lifestyle 
and wellbeing apps, accompanying the document GREEN PAPER on mobile Health ("mHealth"), 
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83 The New England Center for Investigative Reporting, Boston University, "Lacking regulation, many 
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84 https://www.happtique.com/ (online), accessed: 24 Nov.2019 
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86 J. Torous, L.W. Roberts,(2017), Needed innovation in digital health and smartphone applications for 
mental health transparency and trust JAMA Psychiatry, 74 (5) (2017), pp. 437-438,  
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reports87. The majority of those apps use informative and educating to the user 
content in order to allow a comprehensive and interactive experience and observation 
of one’s progress dealing with several mental struggles, the most common being 
depression (e.g. at the 18% of mental health app targets depression while being on the 
top 3 of the mental health apps with the most market potential for 2017).88 
The popularity and quick emergence of the extensive use of mobile health 
applications and platforms for mitigating mental health issues lead the FDA in the US 
to issue a policy relating to three distinctive categories of mental health apps: a) those 
that do not constitute a medical device, b) those that are medical devices according to 
the FDA but it upholds the right to exercise enforcement discretion (that are not 
regulated), c) those that do constitute medical devises and fall under FDA’s regulatory 
jurisdiction.89 As a result, the majority of such applications in the US are not regulated 
which means that they are under no serious inspection and control. In an effort to 
provide with some guidance the Federal Trade Commission came up with a list of 
suitable practices that should be taken under consideration from the manufacturers of 
mental health apps, amongst them being the collection of the minimum amount of 
data from the user and limiting the access and permission to the user’s mobile 
device.90 
  Consequently, upon the absence of federal regulation or an inclusive legal 
framework, such kinds of applications often lack in privacy policies, which appear to be 
insufficient or completely non-existent. Such is the outcome of a study conducted in 
regard to the mental health apps provided to patients suffering from dementia. The 
results pointed out that the apps using a privacy policy were below 50% and even if 
they did it was also lacking in information about the handling of the user’s data.91 
However, this research was based only upon a certain kind of application, specified for 
dementia as a condition, while at the same time extensive research on the field with a 
central focus on depression, due to its widespread nature, was performed to provide 
with answers to major issues, like privacy and security. The results of the review of a 
quarter of the available mental health apps for depression were alarmingly displaying 
the fact that only 4% of those apps had a complete with sufficient information privacy 
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accessed: 24. Nov.19. 
89 Policy for Device Software Functions and Mobile Medical Applications 
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90 Federal Trade Commission (2016, June 24) Mobile Health App Developers: FTC Best Practices, Federal 
Trade Commission,  www.ftc.gov/tips-advice/business-center/guidance/mobile-health-app-developers-
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policy, whereas 68% of them were not adequately transparent with their handling of 
users data. At the same time, a little bit more than 50% did not possess a privacy policy 
at all and from the apps that did have one it was usually provided to the user after the 
collection of information, resulting in the acquiring of data without priory alerting the 
user on the manner in which they will be used.92  
 
3. ARTIFICIAL INTELLIGENCE/AI 
 
According to the definition in the Oxford Dictionary AI is considered: “the 
theory and development of computer systems able to perform tasks normally 
requiring human intelligence, such as visual perception, speech recognition, decision-
making, and translation between languages.”  In the era of big data, AI can contribute 
to the early prediction and response to disease predisposition and spreading, has the 
ability to detect patterns and educate itself from prior experience, ameliorating and 
altering its reaction to future cases.93 
AI alongside robotics constitutes a revolutionary and promising technology 
capable of adding to the progress of humankind, while at the same time exists right at 
the centre of new challenges and questions, regarding its lawful function, ethical 
nature, and economical prospect. More specifically, in the healthcare sector the 
capacity to analyse a vast collection of patient data and produce automatically tailored 
made decisions, usually from a distance, not only can facilitate the process of medical 
decision making but also democratise it, as an increasing number of patients will have 
access to more personalised medicine, especially on the medical field of oncology.94 
However, this also raises ethical questions, regarding informed consent, and the right 
to have the information explained in a comprehensive way, as well as rights of privacy 
and in relation to processing sensitive information.  
 
3.1 AI AND THE EU 
 
 The initiating step in the EU was made in 2016 when the European Parliament’s 
Committee on Legal Affairs (JURI) published the draft report on “Civil Law Rules on 
Robotics”,95 which was later adopted by the European Parliament in 2017 with 
recommendations to the European Commission.96 The latter in April 2018 took a 
                                               
92 • Kristen O'Loughlinab , Martha Nearybc , Elizabeth C.Adkinsb , Stephen M.Schueller, ( 2019), 
Reviewing the data security and privacy policies of mobile apps for depression, Internet Interventions, 
Volume 15, March 2019, Pages 110-115, https://doi.org/10.1016/j.invent.2018.12.001 
93https://www.lexology.com/library/detail.aspx?g=4284727f-3bec-43e5-b230-fad2742dd4fb (online) 
accessed: 26 Nov 19.  
94 Furlow, B. (2016, March 2015). IBM Watson Collaboration Aims to Improve Oncology Decision 
Support Tools.http://www.cancernetwork.com/mbcc-2016/ibm-watson-collaboration-aims-improve-
oncologydecision-support-tools (online) accessed: 26 Nov.19 
95 EU Committee on Legal Affairs. (2016). Draft report with recommendations to the Commission on 
Civil Law Rules on Robotics. May 31 
96 European Parliament resolution of 16 February 2017 with recommendations to the Commission on 
Civil Law Rules on Robotics (2015/2103(INL)), http://www.europarl.europa.eu/doceo/document/TA-8-
2017-0051_EN.html (online) accessed: 26 Nov.19 
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leading step towards the development of a framework for AI in the EU and established 
a strategy (pursuant to the agreement of 24 Member States and Norway on AI - 
European Commission Communication on “Artificial Intelligence for Europe97) to 
establish the principles and values upon which AI should be based upon, with explicit 
reference to the GDPR and Article 2 of the Treaty on EU, focusing on a humanitarian 
approach, based on justice, non- discrimination and freedom.  
  Through that Communication, the Commission announced the creation of an 
independent High – Level Expert Group on AI (AI HLEG)98 and an initiative called AI 
Alliance.99  The AI HLEG produced documents concerning ethical principles that should 
determine the AI’s function together with a definition for this kind of technology. The 
first document on trustworthy AI by the AI HLEG, and the ethical guidelines for it, is the 
“Ethics Guidelines for Trustworthy AI”100 and it also constitutes a part of the latest 
Communication of the EU Commission (Communication: Building Trust in Human-
Centric Artificial Intelligence101), both published on 8th of April 2019. The guidelines 
point out three fundamental components for the achievement of trustworthy AI: a) 
compliance with the law, b) fulfillment of ethical principles and c) robustness.  
Apart from these key factors, the AI HLEG produced 7 key principles and requirements 
relating to ethical and trustworthy AI. 
These requirements are:  
1. Human agency and oversight  
2. Technical robustness and safety 
3. Privacy and data governance 
4. Transparency 
5. Diversity, non-discrimination, and fairness 
6. Societal and Environmental well-being  
7. Accountability  
 
In relation to the general launching of the EU’s strategy for the emerging technological 
innovation that is AI technology, the AI HLEG proposed also a definition for this kind of 
technology, with its document “A definition of AI: Main capabilities and scientific 
disciplines”102, taking into account both its role as a software but also as a scientific 
discipline, . The definition proposed is the following:  
“Artificial intelligence (AI) systems are software (and possibly also hardware) systems 
designed by humans that, given a complex goal, act in the physical or digital dimension 
by perceiving their environment through data acquisition, interpreting the collected 
structured or unstructured data, reasoning on the knowledge, or processing the 
                                               
97European Commission https://ec.europa.eu/digital-single-market/en/news/communication-artificial-
intelligence-europe(online) accessed: 226 Nov.19 
98 AI HLEGhttps://ec.europa.eu/digital-single-market/en/news/ethics-guidelines-trustworthy-ai (online) 
accessed: 26 Nov 19.  
99 https://ec.europa.eu/digital-single-market/en/european-ai-alliance (online) accessed: 26 Nov 19. 
100https://ec.europa.eu/digital-single-market/en/news/ethics-guidelines-trustworthy-ai (online) 
accessed: 26 Nov 19 
101https://ec.europa.eu/digital-single-market/en/news/communication-building-trust-human-centric-
artificial-intelligence (online) accessed: 26 Nov 19. 
102https://ec.europa.eu/digital-single-market/en/news/definition-artificial-intelligence-main-
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information, derived from this data and deciding the best action(s) to take to achieve 
the given goal. AI systems can either use symbolic rules or learn a numeric model, and 
they can also adapt their behavior by analyzing how the environment is affected by 
their previous actions. 
As a scientific discipline, AI includes several approaches and techniques, such as 
machine learning (of which deep learning and reinforcement learning are specific 
examples), machine reasoning (which includes planning, scheduling, knowledge 
representation and reasoning, search, and optimization), and robotics (which includes 
control, perception, sensors and actuators, as well as the integration of all other 
techniques into cyber-physical systems)”.  
 Last but not least, the independent advisory body to the President of the 
European Commission, the European Group on Ethics in Science and New 
Technologies, created also a document on Artificial Intelligence, Robotics and 
“Autonomous Systems”103, highlight similar principles together with safety, security, 
physical and mental integrity, and sustainability.  
 
3.2 AI AND THE US 
 
  The US’s approach to Artificial Intelligence is more business orientated, 
favorizing private stakeholders in the field, such as leading tech giants and innovative 
universities. It’s AI policy is base on Research & Development, since in October 2016 
the White House issued a report on USA’s strategy for AI, “Preparing for the Future of 
Artificial Intelligence”104, followed by two additional reports, one on R&D105 and one 
on Economics. Its overall tone is confident, addressing both the public and the 
technological sector, stressing the need for “ a good AI society”, where AI works for 
the benefit of the people and the government appears not to provide with federal 
regulation, but a rather peripheral scope of action, not wanting to hamper the 
progress of innovation and research, which will boost the US economy to the future. 
Instead, even though not explicitly mentioned in the report, the US government’s 
strategy is in favor of a more self- regulatory approach, according to which the 
institutionalization of members of the private sector will aid in formin the necessary 
values and ethical principles for AI’s proper use. However, with the absence of federal 
regulation, the ability of one to self-regulate raises a concern for the lack of inclusivity 
and protection of all parties concerned in the process, as such a strategy appears more 
favorable only to large private tech corporations, to regulate themselves at their own 
discretion.  
                                               
103https://ec.europa.eu/info/sites/info/files/european_group_on_ethics_ege/ege_ai_statement_2018.p
df (online) accessed: 26 Nov 19 
104 Executive Office of the President National Science and Technology Council Committee on 
Technology. (2016). Preparing for the Future of Artificial Intelligence. Washington D.C. USA. 
https://www.whitehouse.gov/sites/default/files/whitehouse_files/microsites/ostp/NSTC/preparing_for
_the_future_of_ai.pdf  (online) accessed: 27 Nov 19 
105 The OSTP’s companion document, entitled the “National Artificial Intelligence Research and 
Development Strategic Plan”, details how R&D investments can be used to advance policies that have a 
positive long term impact on society and the world. 2016, pp. 7-10. 
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A similar intent and tactic continue in May 2018106 with the announcement of 
the White House to sustain the American Leadership on the field of AI through the 
promotion of public R&D and the removing of obstacles to innovative efforts. 
Consequently, the reluctance of federal legislators to produce a solid regulatory 
framework on AI lead in January 2019 the private sector to take up the initiative. 
Accenture107, an American company, published a report drafting the framework 
needed to aid the federal agencies in the evaluation, development, and monitoring of 
systems such as AI.  In addition, US’s Defense Advanced Research Projects Agency 
(DARPA), launched a programme/ campaign called “ AI Next”108 in order to tackle 
issues impeding the progress of AI technology, such as extreme dependence on data, 
incapacity of explaining the results and obstacles relating to lack of understanding of 
the overall context provided by AI systems.  
The data privacy concerns, although, are usually dealt with through the 
fractional US data protection system, one that is appointed to two different bodies. 
The Federal Communications Commission (FCC) and the Federal Trade Commission 
(FTC) are responsible for sanctions relating to privacy rights infringement109 while at 
the same time seek out to eliminate unjustly and deceiving practices from the market, 
which due to its duality as a system hampers the general function of the industry.  
 
 
3.3 AI AND ETHICS 
 
In the last five years, and especially from 2016 and after, according to the 
results of a study published in nature machine intelligence, there is an increasing 
number of guidelines issued (soft-law), concerning the ethical aspect of AI 
technology.110 According to the study, conducted on 84 documents relating to ethical 
guidelines on AI, there is a mutual interest that it is emerging in the global community, 
deriving both from the private and the public sector.  
To elaborate more, there can be observed an increase in the number of 
documents referring to ethical issues of AI technology produced by various important 
stakeholders such as private companies, governmental committees, academic and 
research institutes, as well as non-governmental organizations. Based on the study, the 
result was that the majority of the above-mentioned documents derive from the most 
developed countries, able to sustain the largest economies. First, amongst them, is the 
US, followed by the UK, Japan, Germany, France, and Finland.111 However, there is a 
                                               
106 https://www.whitehouse.gov/ai/ (online) accessed: 27 Nov 19 
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110 Jobin, A., Ienca, M. & Vayena, E. The global landscape of AI ethics guidelines. Nat Mach Intell 1, 389–
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111 Jobin, A., Ienca, M. & Vayena, E. The global landscape of AI ethics guidelines. Nat Mach Intell 1, 389–
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France and Finland 3.6% each.  
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lack of inclusivity in the representation coming from the global community, like Africa 
and in general, the South American and the countries in Asia are not represented in 
the international debate for ethics and AI. As a result, an environment of imbalance of 
power is created and maintained in the international forum, which not only does not 
promote convergence towards a united global approach but also leaves little space to 
local knowledge and cultural pluralism to develop, resulting in fostering inequality 
worldwide  
 
As far as it comes to the much-needed convergence, as a phenomenon, in fact, it can 
be traced to a global level.  Under thorough examination of the documents produced 
as guidelines, one can reach to two major conclusions, relating to how the 
international community handles and approaches technological breakthroughs, like AI 
technology. Firstly, there can be observed a visible according and convergence as five 
dominant principles emerge, from the comparison of the guideline documents. These 
are a) the principle of transparency, b) the principle of justice, c) the principle of non- 
maleficence, d) the principle of responsibility and e) the principle of privacy.   
On the other hand, several other issues seem to be emerging, concerning an alarming 
contradiction and divergence related to several aspects of these principles.   The first 
of them relates to the problem of how to interpret the principles that have been 
produced. Second, a controversy has arisen regarding why those principles are 
considered valuable and important. Third, there exists an obstacle that has to do with 
what domain, topic or factor these principles should be thought in relation with. Lastly, 
an important barrier and concern refer to their implementation in general.   
Consequently, there derives a need for a global consensus and coordination on these 
matters, relating to the ethical aspect and questions produced from AI technology. In 
this effort, a critical and central role must be given to the international organizations, 
responsible for the promoting of cooperation and mutual understanding, while at the 
same time the cultural and ethical plurality should not be sacrificed in the process of 
achieving total uniformity. 
 
 
3.4 AI AND ROBOTICS IN HEALTHCARE  
 
Robots and robotics, in general, have become a part of everyday life, being 
increasingly incorporated in every sector and the healthcare sector is no exception. 
With the significant progress of medicine and the overly challenging working life of 
adults, there is a need to find new ways to care for the elderly and children in our 
society. Personal Care robots have been proposed as an innovative solution, able to 
care for the aforementioned groups of the population, providing assistance, nurturing 
practices and having anti-stress effects112.  
Personal care robots and companion robots have many uses. They can be providers of 
assistance for clinical and rehabilitation purposes and serve as an aid to memory, as 
well as play the role of caretakers responsible for bringing medicine and food to the 
                                               
112 Alemi, M., Meghdari, A. & Saffari, E. (2017). RoMa: A hi-tech robotic mannequin for the fashion 
industry. Lecture Notes in Computer Science (LNCS): Social Robotics, 10652, 209-219. 
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elderly. Such cases of innovative machinery are the RI-MAN, PaPeRo, and the Care-O-
bot.113The latter114 is designed to navigate itself around the house, to facilitate opening 
doors and to be able to complete tasks such as the procurement of drinks and 
beverages. Robert115 is also an example of a care nursing robot, of an experimental 
nature, which has the size of a human and the appearance of a teddy-bear and can lift 
patients from their beds in order to place them in their wheelchair.  
Apart from these types of advanced robots, robotics in healthcare has already been 
dominated by other types of technological innovations, such as prostheses but most 
importantly surgical robots, the most famous amongst them being the da Vinci system, 
created by Intuitive Surgical Inc. The da Vinci system116 allows the doctor, through the 
use of a console, to have a 3D image of the patient and control of three surgical 
instruments and a forth which is used as a camera, allowing for a more precise, less 
restricted and safe movement of the operator’s hands. However, this is not without its 
challenges, as operating such a machine needs training and time to master and a 3D 
image is also significantly different than the real-life experience of a doctor able to 
actually feel the patient. 
Consequently, concern has risen from the incorporation of AI in healthcare, as 
healthcare will be dehumanized if machines are to replace human contact and 
communication. In addition, there are some legal issues to be examined from this shift 
towards a more AI and robotic dominated the healthcare sector. For instance, it is 
quite clear in the cases of prosthetics and surgical robots that specific Directives can be 
applied, such as the Council Directive 93/42/EEC concerning medical devices (as 
amended by Directive 2007/47/EC) (“Medical Device Directive”117) and the Council 
Directive 90/385/EEC on the approximation of the laws of the Member States relating 
to active implantable medical devices (“AIMDD”). On the contrary, the legal framework 
for care robots is not so clear. More specifically, some of them, depending on the 
service that they provide, could be regulated by the Medical Device Directive, as their 
aim is to provide with services of medicinal nature (e.g. reminding elders to take their 
medication), but others with a more general use, as movement facilitators, might not 
fit the definition of a medical device, thus they will be excluded from the Directive’s 
scope.  
 The major problem with the aforementioned categories of robots and AI systems is 
that while their owner uses them, they keep collecting and processing data of that 
specific user. The storage of such sensitive information (e.g. a patient’s medication, 
health status, and biometric information), might be necessary for the robot to process 
and to use in making suggestions or producing desirable results, while simultaneously 
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the cloud storage of such data might be perilous in terms of safeguarding one’s 
privacy.  
In the Civil Law Rules on Robotics, adopted by the European Parliament in 2017, there 
are specific references made on how care and medical, as well as human repair and 
enhancement robotics, should be properly handled. Emphasis is given, in the cases of 
care robots, in the need for the human factor to remain present and in charge of the 
care of patients, without allowing the robots to replace human care and interaction. 
Regarding medical robots, the focus of the framework was on the specific training and 
certification of the sergeants in order to be able to operate with the aid of robotics 
safely. Finally, the purpose of human prosthetics is to ameliorate human life and 
facilitate it, while ensuring that any mechanism introduced into the human body 
cannot harm its host and that all members of society have proper and equal access to 
them. 
 
 
 
Conclusions 
 
In a world of opportunity and innovation, cutting-edge research and 
technological advancement are only but natural to develop at the same time a lot of 
concerns regarding towards what direction this progress can lead to. Without a doubt, 
the ever-changing world of technology and the growing industry by itself are what 
alarmed European and national legislators, guiding them to re-evaluate existing norms 
and legal frameworks. The General Data Protection Regulation was the product of such 
a need, of the law to be in sync with the modern era and not fall behind, risking to 
leave a great part of society unprotected. However, historically legislation was never 
so fast in updating itself to meet the demands of its time. Today constitutes no 
exception. 
 Modern technology has provided numerous possibilities, previously dwelling only in 
the realm of science fiction. Direct-to-consumer genetic testing, mobile health 
applications, serving various purposes and directed even to mental health conditions, 
as well as big data analysis and AI technology successfully applicable in healthcare, are 
only some of the pioneering ways technological progress has influenced the lives and 
most importantly the health status of billions. The legal framework following this 
progress appears to be less prepared to cover the novelties emerging every day. On 
the contrary, legislators opt for a soft-law approach to the issue, fearing to impede the 
process of research and development, while there is still a need for a solid legal 
foundation, countries and the public can depend upon.  
 
Regarding ethics and guidelines, a serious effort has been made, in the past few years, 
towards international coordination and acceptance of the same principles, even 
though there is much more to be achieved towards that direction. Privacy, in fact, 
appears to be a key principle for the majority of the global community, hence the need 
to regulate it further. However, judging from the fact that new ways for infringing this 
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right occur with the creation of technological projects, surpassing the capacities of the 
previous ones (e.g. big data analysis in health care, robotics storing sensitive 
information), specialization and updating of the legal framework is more than 
necessary, if true protection of privacy is to be achieved.  
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